The inhibitory effect of ellagic acid on cell growth of ovarian carcinoma cells

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Chung, Yuan Chiang ^a   Lu, Li Cheng ^b   Tsai, Ming Hsiu ^c   Chen, Yu Jen ^c   Chen, Yi Ying ^c   Yao, Shih Ping ^c   Hsu, Chih Ping ^c  

^a CHENG CHING GENERAL HOSPITAL   (Taiwan)

^b TAOYUAN GENERAL HOSPITAL   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; DOXORUBICIN; ELLAGIC ACID; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLS; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 84880164349     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/306705     Document Type: Article

References (31)

1. Deraco M., Baratti D., Laterza B., Balestra M. R., Mingrone E., MacRì A., Virzì S., Puccio F., Ravenda P. S., Kusamura S., Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. European Journal of Surgical Oncology 2011 37 1 4 9 2-s2.0-78650284840 10.1016/j.ejso.2010.11.004
2. Gómez-Raposo C., Mendiola M., Barriuso J., Hardisson D., Redondo A., Molecular characterization of ovarian cancer by gene-expression profiling. Gynecologic Oncology 2010 118 1 88 92 2-s2.0-77953288814 10.1016/j.ygyno.2010. 03.012
3. Cohen M., Dromard M., Petignat P., Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecologic Oncology 2010 119 1 164 166 2-s2.0-77956651448 10.1016/j.ygyno.2010.05.027
4. HHLW (Ministry of Health, Labor and Welfare of Japan),. List of Existing Food Additives, Notification No. 120 of the Ministry of Health and Welfare, 1996
5. Losso J. N., Bansode R. R., Trappey A. II, Bawadi H. A., Truax R., In vitro anti-proliferative activities of ellagic acid. Journal of Nutritional Biochemistry 2004 15 11 672 678 2-s2.0-10044262012 10.1016/j.jnutbio.2004.06.004 (Pubitemid 39611365)
6. Larrosa M., Tomás-Barberán F. A., Espín J. C., The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. Journal of Nutritional Biochemistry 2006 17 9 611 625 2-s2.0-33747026663 10.1016/j.jnutbio.2005.09.004 (Pubitemid 44205438)
7. Tasaki M., Umemura T., Maeda M., Ishii Y., Okamura T., Inoue T., Kuroiwa Y., Hirose M., Nishikawa A., Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food and Chemical Toxicology 2008 46 3 1119 1124 2-s2.0-38649087345 10.1016/j.fct.2007.10.043
8. Malik A., Afaq S., Shahid M., Akhtar K., Assiri A., Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway. Asian Pacific Journal of Tropical Medicine 2011 4 7 550 555 2-s2.0-79960873482 10.1016/S1995-7645(11)60144-2
9. Edderkaoui M., Odinokova I., Ohno I., Gukovsky I., Go V. L. W., Pandol S. J., Gukovskaya A. S., Ellagic acid induces apoptosis through inhibition of nuclear factor B in pancreatic cancer cells. World Journal of Gastroenterology 2008 14 23 3672 3680 2-s2.0-54349088525 10.3748/wjg.14.3672
10. Li T.-M., Chen G.-W., Su C.-C., Lin J.-G., Yeh C.-C., Cheng K.-C., Chung J.-G., Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Research 2005 25 2 A 971 979 2-s2.0-17444408529 (Pubitemid 40546871)
11. Fjaeraa C., Nånberg E., Effect of ellagic acid on proliferation, cell adhesion and apoptosis in SH-SY5Y human neuroblastoma cells. Biomedicine and Pharmacotherapy 2009 63 4 254 261 2-s2.0-64749108144 10.1016/j.biopha.2008. 07.093
12. Kim S., Liu Y., Gaber M. W., Bumgardner J. D., Haggard W. O., Yang Y., Development of chitosan-ellagic acid films as a local drug delivery system to induce apoptotic death of human melanoma cells. Journal of Biomedical Materials Research 2009 90 1 145 155 2-s2.0-67650783898 10.1002/jbm.b.31266
13. Mishra S., Vinayak M., Anti-carcinogenic action of ellagic acid mediated via modulation of oxidative stress regulated genes in Dalton lymphoma bearing mice. Leukemia and Lymphoma 2011 52 11 2155 2161 2-s2.0-80055001945 10.3109/10428194.2011.591014
14. Kern D. H., Morgan C. R., Hildebrand-Zanki S. U., In vitro pharmacodynamics of 1- β -D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Research 1988 48 1 117 121 2-s2.0-0023945379 (Pubitemid 18030339)
15. Chung Y.-C., Lin C.-C., Chou C.-C., Hsu C.-P., The effect of Longan seed polyphenols on colorectal carcinoma cells. European Journal of Clinical Investigation 2010 40 8 713 721 2-s2.0-77954532077 10.1111/j.1365-2362.2010. 02322.x
16. Böck B. C., Tagscherer K. E., Fassl A., Krämer A., Oehme I., Zentgraf H.-W., Keith M., Roth W., The PEA-15 protein regulates autophagy via activation of JNK. Te Journal of Biological Chemistry 2010 285 28 21644 21654 2-s2.0-77954381442 10.1074/jbc.M109.096628
17. Chung Y.-C., Chang K.-J., Yang C.-C., Lai M.-T., Hsu C.-P., Hsueh S.-F., Peng C.-C., Fu H.-H., Chang Y.-F., Yang S.-D., Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer 2002 95 9 1840 1847 2-s2.0-0036839664 10.1002/cncr.10904 (Pubitemid 35222162)
18. Yang Z. J., Chee C. E., Huang S., Sinicrope F. A., The role of autophagy in cancer: therapeutic implications. Molecular Cancer Therapeutics 2011 10 9 1533 1541 2-s2.0-80052697287 10.1158/1535-7163.MCT-11-0047
19. Mertens-Talcott S. U., Bomser J. A., Romero C., Talcott S. T., Percival S. S., Ellagic acid potentiates the effect of quercetin on p21 waf1/cip1, p53, and MAP-kinases without affecting intracellular generation of reactive oxygen species in vitro. Journal of Nutrition 2005 135 3 609 614 2-s2.0-14944370013 (Pubitemid 40365226)
20. Weiss R. H., p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003 4 6 425 429 2-s2.0-0347628818 10.1016/S1535-6108(03) 00308-8 (Pubitemid 38050039)
21. Zhang K., Kumar R., Interferon-inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochemical and Biophysical Research Communications 1994 200 1 522 528 2-s2.0-0028177842 10.1006/bbrc.1994.1479
22. Taylor W. R., Stark G. R., Regulation of the G2/M transition by p53. Oncogene 2001 20 15 1803 1815 2-s2.0-0035810054 10.1038/sj.onc.1204252 (Pubitemid 32458690)
23. Vuletic A., Konjevic G., Milanovic D., Ruzdijic S., Jurisic V., Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and BCL-2 protein levels in G0/G1 arrested HL-60 cells. Pathology and Oncology Research 2010 16 3 393 401 2-s2.0-77956886917 10.1007/s12253-009-9241-2
24. Miyazaki T., Arai S., Two distinct controls of mitotic Cdk1/cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 2007 6 12 1419 1425 2-s2.0-38349161010
25. Mano Y., Kikuchi Y., Yamamoto K., Kita T., Hirata J., Tode T., Ishii K., Nagata I., Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. European Journal of Cancer 1999 35 8 1214 1219 2-s2.0-0032794804 10.1016/S0959-8049(99)00124-0 (Pubitemid 29359181)
26. Gilmore A. P., Anoikis. Cell Death and Differentiation 2005 12 2 1473 1477 2-s2.0-27644439209 10.1038/sj.cdd.4401723 (Pubitemid 41553981)
27. Nishikawa T., Tsuno N. H., Okaji Y., Shuno Y., Sasaki K., Hongo K., Sunami E., Kitayama J., Takahashi K., Nagawa H., Inhibition of autophagy potentiates sulforaphane-induced apoptosis in human colon cancer cells. Annals of Surgical Oncology 2010 17 2 592 602 2-s2.0-77149128638 10.1245/s10434-009- 0696-x
28. Hannigan G., Troussard A. A., Dedhar S., Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nature Reviews Cancer 2005 5 1 51 63 2-s2.0-11144225205 10.1038/nrc1524 (Pubitemid 40052325)
29. Parma G., Mancari R., Del Conte G., Scambia G., Gadducci A., Hess D., Katsaros D., Sessa C., Rinaldi A., Bertoni F., Vitali A., Catapano C. V., Marsoni S., van de Velde H., Colombo N., An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. International Journal of Gynecological Cancer 2012 22 5 792 800 10.1097/IGC.0b013e318251051a
30. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., Domingo D., Yahalom J., A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Research 2001 61 2 439 444 2-s2.0-0035863399 (Pubitemid 32128593)
31. Fang J., Nakamura H., Iyer A. K., Tumor-targeted induction of oxystress for cancer therapy. Journal of Drug Targeting 2007 15 7-8 475 486 2-s2.0-34547670578 10.1080/10611860701498286 (Pubitemid 47213870)